Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
izalontamab brengitecan + almonertinib
- Development stage
- Unknown
- Lead developer
- Biokin Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
izalontamab brengitecan + almonertinib is a combination therapy being investigated for the treatment of non-small cell lung cancer (NSCLC), specifically as a neoadjuvant treatment for patients with resectable stage II-IIIB EGFR-mutation positive disease. The regimen consists of izalontamab brengitecan (BL-B01D1), a first-in-class bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3, and almonertinib (aumolertinib), a third-generation EGFR tyrosine kinase inhibitor (TKI). Izalontamab brengitecan utilizes a bispecific antibody linked to a camptothecin-derivative payload (Ed-04), which acts as a topoisomerase I inhibitor, with a drug-to-antibody ratio of 8. Almonertinib provides targeted inhibition of EGFR-sensitizing and resistance mutations. This combination is currently being evaluated in a Phase II clinical trial sponsored by Sichuan University (West China Hospital) to assess its safety and efficacy in the neoadjuvant and adjuvant settings.
- Other names
- izalontamab brengitecan + aumolertinibBL-B01D1 + aumolertinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on izalontamab brengitecan + almonertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on izalontamab brengitecan + almonertinib.